<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39399191</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2000-9666</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>5</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Journal of community hospital internal medicine perspectives</Title><ISOAbbreviation>J Community Hosp Intern Med Perspect</ISOAbbreviation></Journal><ArticleTitle>COVID-19-related Pneumonitis in Immunocompromised Patients: Reviewing Clinical Features and Management Approaches.</ArticleTitle><Pagination><StartPage>63</StartPage><EndPage>72</EndPage><MedlinePgn>63-72</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.55729/2000-9666.1399</ELocationID><Abstract><AbstractText>In this case series, we explore persistent SARS-CoV-2 infection and its resultant pneumonitis within a cohort of immunocompromised patients. We elucidate the complex interplay between immunosuppression and COVID-19 by examining four patients who experienced prolonged viral shedding and recurrent respiratory failure due to their compromised immune systems. This series elucidates the clinical presentation, diagnostic challenges, and therapeutic strategies. We also summarize existing literature regarding persistent SARS-CoV-2 infection in immunocompromised individuals. Our findings support the use of a tailored treatment approach using a proposed diagnostic and management algorithm to standardize care and optimize outcomes.</AbstractText><CopyrightInformation>© 2024 Greater Baltimore Medical Center.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nasrullah</LastName><ForeName>Adeel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Allegheny Health Network, Pittsburgh, PA, 15212, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shakir</LastName><ForeName>Hassan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>The Wright Center of Graduate Medical Education, Scranton, PA, 18505, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Eiraj</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Allegheny Health Network, Pittsburgh, PA, 15212, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bilal</LastName><ForeName>Muhammad I</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Allegheny Health Network, Pittsburgh, PA, 15212, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheikh</LastName><ForeName>Abu B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of New Mexico, Albuquerque, NM 87106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malik</LastName><ForeName>Khalid</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Allegheny Health Network, Pittsburgh, PA, 15212, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheema</LastName><ForeName>Tariq</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Allegheny Health Network, Pittsburgh, PA, 15212, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Community Hosp Intern Med Perspect</MedlineTA><NlmUniqueID>101601396</NlmUniqueID><ISSNLinking>2000-9666</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Covid-19</Keyword><Keyword MajorTopicYN="N">Immunocompromised</Keyword><Keyword MajorTopicYN="N">Pneumonitis</Keyword></KeywordList><CoiStatement>Conflict of interest: The authors report no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>7</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39399191</ArticleId><ArticleId IdType="pmc">PMC11466343</ArticleId><ArticleId IdType="doi">10.55729/2000-9666.1399</ArticleId><ArticleId IdType="pii">jchim-14-05-063</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baang JH, Smith C, Mirabelli C, et al. Prolonged severe acute respiratory syndrome coronavirus 2 replication in an immunocompromised patient. J Infect Dis. 2021;223(1):23–27. doi: 10.1093/infdis/jiaa666.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa666</ArticleId><ArticleId IdType="pmc">PMC7797758</ArticleId><ArticleId IdType="pubmed">33089317</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrati C, Bartolini B, Bordoni V, et al. Emerging viral infections in immunocompromised patients: a great challenge to better define the role of immune response. Front Immunol. 2023;14:1147871. doi: 10.3389/fimmu.2023.1147871.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1147871</ArticleId><ArticleId IdType="pmc">PMC10035572</ArticleId><ArticleId IdType="pubmed">36969202</ArticleId></ArticleIdList></Reference><Reference><Citation>Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe. 2021;2(1):e13–e22. doi: 10.1016/S2666-5247(20)30172-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(20)30172-5</ArticleId><ArticleId IdType="pmc">PMC7837230</ArticleId><ArticleId IdType="pubmed">33521734</ArticleId></ArticleIdList></Reference><Reference><Citation>Parotto M, Gyöngyösi M, Howe K, et al. Post-acute sequelae of COVID-19: understanding and addressing the burden of multisystem manifestations. Lancet Respir Med. 2023;11(8):739–754. doi: 10.1016/S2213-2600(23)00239-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(23)00239-4</ArticleId><ArticleId IdType="pubmed">37475125</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601–615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Dioverti V, Salto-Alejandre S, Haidar G. Immunocompromised patients with protracted COVID-19: a review of “long persisters”. Curr Transplant Rep. 2022;9(4):209–218. doi: 10.1007/s40472-022-00385-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40472-022-00385-y</ArticleId><ArticleId IdType="pmc">PMC9660019</ArticleId><ArticleId IdType="pubmed">36407883</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, Rosas IO, Singer M. Understanding post-COVID-19 interstitial lung disease (ILD): a new fibroinflammatory disease entity. Intensive Care Med. 2022;48(12):1803–1806. doi: 10.1007/s00134-022-06877-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-022-06877-w</ArticleId><ArticleId IdType="pmc">PMC9453725</ArticleId><ArticleId IdType="pubmed">36074167</ArticleId></ArticleIdList></Reference><Reference><Citation>Corvol H, Alimi A, Prevost B, et al. Atypical severe organizing pneumonia following coronavirus disease 2019 in an immunocompromised teenager. Clin Infect Dis. 2022;74(5):938–939. doi: 10.1093/cid/ciab657.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab657</ArticleId><ArticleId IdType="pubmed">34309637</ArticleId></ArticleIdList></Reference><Reference><Citation>Łyżwa E, Sobiecka M, Lewandowska K, et al. Prolonged SARS-CoV-2 infection and organizing pneumonia in a patient with follicular lymphoma, treated with obinutuzumab—challenging recognition and treatment. Viruses. 2023;15(3):693. doi: 10.3390/v15030693.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15030693</ArticleId><ArticleId IdType="pmc">PMC10051526</ArticleId><ArticleId IdType="pubmed">36992402</ArticleId></ArticleIdList></Reference><Reference><Citation>Aesif SW, Bribriesco AC, Yadav R, et al. Pulmonary pathology of COVID-19 following 8 Weeks to 4 Months of severe disease: a report of three cases, including One with bilateral lung transplantation. Am J Clin Pathol. 2021;155(4):506–514. doi: 10.1093/ajcp/aqaa264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcp/aqaa264</ArticleId><ArticleId IdType="pmc">PMC7799292</ArticleId><ArticleId IdType="pubmed">33316056</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford ES, Simmons W, Karmarkar EN, et al. Successful treatment of prolonged, severe coronavirus disease 2019 lower respiratory tract disease in a B cell acute lymphoblastic leukemia patient with an extended course of remdesivir and nirmatrelvir/ritonavir. Clin Infect Dis. 2023;76(5):926–929. doi: 10.1093/cid/ciac868.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac868</ArticleId><ArticleId IdType="pmc">PMC10226728</ArticleId><ArticleId IdType="pubmed">36326680</ArticleId></ArticleIdList></Reference><Reference><Citation>Le DT, Vu VH, Nguyen DH, et al. Late onset of organizing pneumonia following SARS-CoV-2 infection: a case report of successful management and review literature. Clin Med Insights Case Rep. 2023;16:117954762311521. doi: 10.1177/11795476231152166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/11795476231152166</ArticleId><ArticleId IdType="pmc">PMC9884631</ArticleId><ArticleId IdType="pubmed">36721729</ArticleId></ArticleIdList></Reference><Reference><Citation>Hettle D, Hutchings S, Muir P, Moran E. Persistent SARSCoV-2 infection in immunocompromised patients facilitates rapid viral evolution: retrospective cohort study and literature review. Clin Infect Pract. 2022;16:100210. doi: 10.1016/j.clinpr.2022.100210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinpr.2022.100210</ArticleId><ArticleId IdType="pmc">PMC9666269</ArticleId><ArticleId IdType="pubmed">36405361</ArticleId></ArticleIdList></Reference><Reference><Citation>Maison DP, Deng Y, Gerschenson M. SARS-CoV-2 and the host-immune response. Front Immunol. 2023;14:1195871. doi: 10.3389/fimmu.2023.1195871.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1195871</ArticleId><ArticleId IdType="pmc">PMC10315470</ArticleId><ArticleId IdType="pubmed">37404823</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinicci M, Mazzoni A, Borchi B, et al. AIDS patient with severe T cell depletion achieved control but not clearance of SARS-CoV-2 infection. Eur J Immunol. 2022;52(2):352–355. doi: 10.1002/eji.202149574.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.202149574</ArticleId><ArticleId IdType="pmc">PMC9015404</ArticleId><ArticleId IdType="pubmed">34822185</ArticleId></ArticleIdList></Reference><Reference><Citation>Gafter-Gvili A, Polliack A. Bendamustine associated immune suppression and infections during therapy of hematological malignancies. Leuk Lymphoma. 2016;57(3):512–519. doi: 10.3109/10428194.2015.1110748.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/10428194.2015.1110748</ArticleId><ArticleId IdType="pubmed">26696321</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn G, Klapsa D, Wilton T, Stone L, Minor PD, Martin J. Twenty-eight years of poliovirus replication in an immunodeficient individual: impact on the global polio eradication initiative. Racaniello V PLoS Pathog. 2015;11(8):e1005114. doi: 10.1371/journal.ppat.1005114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1005114</ArticleId><ArticleId IdType="pmc">PMC4552295</ArticleId><ArticleId IdType="pubmed">26313548</ArticleId></ArticleIdList></Reference><Reference><Citation>Wislez M, Sibony M, Naccache JM, et al. Organizing pneumonia related to common variable immunodeficiency. Respiration. 2000;67(4):467–470. doi: 10.1159/000029552.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000029552</ArticleId><ArticleId IdType="pubmed">10940808</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedskog C, Rodriguez L, Roychoudhury P, et al. Viral resistance analyses from the remdesivir phase 3 adaptive COVID- 19 treatment trial-1 (ACTT-1) J Infect Dis. 2023;228(9):1263–1273. doi: 10.1093/infdis/jiad270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiad270</ArticleId><ArticleId IdType="pmc">PMC10629708</ArticleId><ArticleId IdType="pubmed">37466213</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown LAK, Moran E, Goodman A, et al. Treatment of chronic or relapsing COVID-19 in immunodeficiency. J Allergy Clin Immunol. 2022;149(2):557–561e1. doi: 10.1016/j.jaci.2021.10.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2021.10.031</ArticleId><ArticleId IdType="pmc">PMC8585958</ArticleId><ArticleId IdType="pubmed">34780850</ArticleId></ArticleIdList></Reference><Reference><Citation>Trottier CA, Wong B, Kohli R, et al. Dual antiviral therapy for persistent coronavirus disease 2019 and associated organizing pneumonia in an immunocompromised host. Clin Infect Dis. 2023;76(5):923–925. doi: 10.1093/cid/ciac847.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac847</ArticleId><ArticleId IdType="pmc">PMC9620374</ArticleId><ArticleId IdType="pubmed">36281907</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow O, Vesterbacka J, Tovatt T, Nowak P. Successful combination treatment for persistent severe acute respiratory syndrome coronavirus 2 infection. Clin Infect Dis. 2023;76(10):1864–1865. doi: 10.1093/cid/ciad085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad085</ArticleId><ArticleId IdType="pubmed">36782402</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruki T, Nomoto H, Iwamoto N, et al. Successful management of persistent COVID-19 using combination antiviral therapy (nirmatrelvir/ritonavir and remdesivir) and intravenous immunoglobulin transfusion in an immunocompromised host who had received CD20 depleting therapy for follicular lymphoma. J Infect Chemother. Jan, 2024. S1341321X24000126. Published online.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiac.2024.01.008</ArticleId><ArticleId IdType="pubmed">38242284</ArticleId></ArticleIdList></Reference><Reference><Citation>Montejano R, Marcelo C, Falces-Romero I, et al. Efficacy of sotrovimab for persistent coronavirus disease-2019 in a severely immunocompromised person living with HIV. AIDS. 2022;36(5):751–753. doi: 10.1097/QAD.0000000000003179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0000000000003179</ArticleId><ArticleId IdType="pubmed">35323160</ArticleId></ArticleIdList></Reference><Reference><Citation>Overbeck V, Taylor BP, Turcinovic J, et al. Successful treatment of SARS-CoV-2 in an immunocompromised patient with persistent infection for 245 days: a case report. Heliyon. 2024;10(1):e23699. doi: 10.1016/j.heliyon.2023.e23699.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2023.e23699</ArticleId><ArticleId IdType="pmc">PMC10784163</ArticleId><ArticleId IdType="pubmed">38223743</ArticleId></ArticleIdList></Reference><Reference><Citation>Wada D, Nakamori Y, Maruyama S, et al. Novel treatment combining antiviral and neutralizing antibody-based therapies with monitoring of spike-specific antibody and viral load for immunocompromised patients with persistent COVID-19 infection. Exp Hematol Oncol. 2022;11(1):53. doi: 10.1186/s40164-022-00307-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40164-022-00307-9</ArticleId><ArticleId IdType="pmc">PMC9462070</ArticleId><ArticleId IdType="pubmed">36085172</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikulska M, Sepulcri C, Dentone C, et al. Triple combination therapy with 2 antivirals and monoclonal antibodies for persistent or relapsed severe acute respiratory syndrome coronavirus 2 infection in immunocompromised patients. Clin Infect Dis. 2023;77(2):280–286. doi: 10.1093/cid/ciad181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad181</ArticleId><ArticleId IdType="pubmed">36976301</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanzafame M, Gottardi M, Guella L, et al. Successful treatment of persistent SARS-CoV-2 infection with nirmatrelvir/ ritonavir plus sotrovimab in four immunocompromised patients. J Chemother. 2023;35(7):623–626. doi: 10.1080/1120009X.2023.2196917.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1120009X.2023.2196917</ArticleId><ArticleId IdType="pubmed">37102326</ArticleId></ArticleIdList></Reference><Reference><Citation>Haidar G, Jacobs JL, Kramer KH, et al. Therapy with allogeneic severe acute respiratory syndrome coronavirus-2–specific T cells for persistent coronavirus disease 2019 in immunocompromised patients. Clin Infect Dis. 2023;77(5):696–702. doi: 10.1093/cid/ciad233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad233</ArticleId><ArticleId IdType="pmc">PMC10495124</ArticleId><ArticleId IdType="pubmed">37078720</ArticleId></ArticleIdList></Reference><Reference><Citation>Brosh-Nissimov T, Ma’aravi N, Leshin-Carmel D, et al. Combination treatment of persistent COVID-19 in immunocompromised patients with remdesivir, nirmaltrevir/ritonavir and tixegavimab/cilgavimab. J Microbiol Immunol Infect. 2023:S1684118223001706. doi: 10.1016/j.jmii.2023.09.004. . Published online September.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2023.09.004</ArticleId><ArticleId IdType="pubmed">37805361</ArticleId></ArticleIdList></Reference><Reference><Citation>Breeden M, Aitken SL, Baang JH, et al. Successful treatment of prolonged severe acute respiratory syndrome coronavirus 2 infection in patients with immunodeficiency with extended nirmatrelvir/ritonavir: case series. Open Forum Infect Dis. 2023;10(4):ofad189. doi: 10.1093/ofid/ofad189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofad189</ArticleId><ArticleId IdType="pmc">PMC10114524</ArticleId><ArticleId IdType="pubmed">37089775</ArticleId></ArticleIdList></Reference><Reference><Citation>Martínez-Chinchilla C, Vazquez-Montero L, Palazón-Carrión N, et al. Persistence of SARS-CoV-2 infection in severely immunocompromised patients with complete remission B-cell lymphoma and anti-CD20 monoclonal antibody therapy: a case report of two cases. Front Immunol. 2022;13:860891. doi: 10.3389/fimmu.2022.860891.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.860891</ArticleId><ArticleId IdType="pmc">PMC9046988</ArticleId><ArticleId IdType="pubmed">35493500</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein D, Oviedo-Orta E, Kampman WA, et al. Compassionate use of REGEN-COV® in patients with coronavirus disease 2019 (COVID-19) and immunodeficiency-associated antibody disorders. Clin Infect Dis. 2022;75(1):e509–e515. doi: 10.1093/cid/ciab1059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab1059</ArticleId><ArticleId IdType="pmc">PMC8755381</ArticleId><ArticleId IdType="pubmed">34971385</ArticleId></ArticleIdList></Reference><Reference><Citation>Franceschini E, Pellegrino M, Todisco V, et al. Persistent SARS-CoV-2 infection with multiple clinical relapses in two patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab. Infection. 2023;51(5):1577–1581. doi: 10.1007/s15010-023-02039-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-023-02039-2</ArticleId><ArticleId IdType="pmc">PMC10115373</ArticleId><ArticleId IdType="pubmed">37076752</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda H, Mori Y, Chiba A, et al. Resolution of one-year persisting COVID-19 pneumonia and development of immune thrombocytopenia in a follicular lymphoma patient with preceding rituximab maintenance therapy: a follow-up report and literature review of cases with prolonged infections. Clin Lymphoma Myeloma Leuk. 2021;21(10):e810–e816. doi: 10.1016/j.clml.2021.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clml.2021.07.004</ArticleId><ArticleId IdType="pmc">PMC8286809</ArticleId><ArticleId IdType="pubmed">34393077</ArticleId></ArticleIdList></Reference><Reference><Citation>Salcedo RM, Flores RG, Medina CA, Mogollon RJ, Madariaga MG. Postinfectious interstitial pneumonia after COVID-19 infection. Infect Dis Clin Pract. 2021;29(3):e193–e194. doi: 10.1097/IPC.0000000000000985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/IPC.0000000000000985</ArticleId><ArticleId IdType="pmc">PMC8115427</ArticleId><ArticleId IdType="pubmed">34191908</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiew HW, Tan JWP, Teo CHY. Delayed organising pneumonia in an immunocompromised host after a mild COVID-19 infection. BMJ Case Rep. 2023;16(5):e254737. doi: 10.1136/bcr-2023-254737.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2023-254737</ArticleId><ArticleId IdType="pmc">PMC10193096</ArticleId><ArticleId IdType="pubmed">37192779</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas Jefferson University. Vahid B. Nonspecific interstitial pneumonitis in HIV-infected patients. Med Forum. 2003;4(1) doi: 10.29046/TMF.004.1.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.29046/TMF.004.1.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Sattler F, Nichols L, Hirano L, et al. Nonspecific interstitial pneumonitis mimicking pneumocystis carinii pneumonia. Am J Respir Crit Care Med. 1997;156(3):912–917. doi: 10.1164/ajrccm.156.3.9612050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm.156.3.9612050</ArticleId><ArticleId IdType="pubmed">9310013</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortazavi S, De Peralta-Venturina M, Marchevsky AM. Nonspecific interstitial pneumonia pattern is a frequent finding in patients with post-acute COVID-19 syndrome treated with bilateral orthotopic lung transplantation: current best evidence. Hum Pathol. 2023;141:90–101. doi: 10.1016/j.humpath.2023.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humpath.2023.06.008</ArticleId><ArticleId IdType="pmc">PMC10290180</ArticleId><ArticleId IdType="pubmed">37364827</ArticleId></ArticleIdList></Reference><Reference><Citation>Konopka KE, Perry W, Huang T, Farver CF, Myers JL. Usual interstitial pneumonia is the most common finding in surgical lung biopsies from patients with persistent interstitial lung disease following infection with SARS-CoV-2. EClinicalMedicine. 2021;42:101209. doi: 10.1016/j.eclinm.2021.101209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101209</ArticleId><ArticleId IdType="pmc">PMC8609167</ArticleId><ArticleId IdType="pubmed">34841234</ArticleId></ArticleIdList></Reference><Reference><Citation>Singhal M, Gaur L, Verma R, Tandon R. Post-CMV organizing pneumonia – an unusual presentation 10 years after kidney transplantation. Indian J Nephrol. 2022;32(5):480. doi: 10.4103/ijn.ijn_254_21.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijn.ijn_254_21</ArticleId><ArticleId IdType="pmc">PMC9775620</ArticleId><ArticleId IdType="pubmed">36568596</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazdyrev E, Panova M, Zherebtsova V, et al. The hidden pandemic of COVID-19-induced organizing pneumonia. Pharmaceuticals. 2022;15(12):1574. doi: 10.3390/ph15121574.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph15121574</ArticleId><ArticleId IdType="pmc">PMC9780828</ArticleId><ArticleId IdType="pubmed">36559025</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan HX, Wong CK, Yik WF, Lam YF, Lachmanan KR. Post COVID-19 organizing pneumonia treated with mycophenolate mofetil. Respirol Case Rep. 2022;10(11):e01042. doi: 10.1002/rcr2.1042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rcr2.1042</ArticleId><ArticleId IdType="pmc">PMC9522637</ArticleId><ArticleId IdType="pubmed">36204457</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanaoka K, Minami S, Ihara S, Tanaka T, Yasuoka H, Komuta K. Secondary organizing pneumonia after coronavirus disease 2019: two cases. Respir Med Case Rep. 2021;32:101356. doi: 10.1016/j.rmcr.2021.101356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmcr.2021.101356</ArticleId><ArticleId IdType="pmc">PMC7868600</ArticleId><ArticleId IdType="pubmed">33598398</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong KW, Yang JW, Kim JD, Ju S, Cho MC, Bae IG. Persistent pneumonic consolidations due to secondary organizing pneumonia in a patient recovering from COVID-19 pneumonia: a case report and literature review. Infect Chemother. 2023;55(1):121. doi: 10.3947/ic.2022.0128.</Citation><ArticleIdList><ArticleId IdType="doi">10.3947/ic.2022.0128</ArticleId><ArticleId IdType="pmc">PMC10079436</ArticleId><ArticleId IdType="pubmed">36731500</ArticleId></ArticleIdList></Reference><Reference><Citation>Martini K, Larici AR, Revel MP, et al. COVID-19 pneumonia imaging follow-up: when and how? A proposition from ESTI and ESR. Eur Radiol. 2022;32(4):2639–2649. doi: 10.1007/s00330-021-08317-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00330-021-08317-7</ArticleId><ArticleId IdType="pmc">PMC8553396</ArticleId><ArticleId IdType="pubmed">34713328</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambati S, Ali B, Seddon O, et al. Resolution of persistent SARS-CoV-2 infection with prolonged intravenous remdesivir and vaccination in a patient post CAR-T. Int J Hematol. 2023;117(5):765–768. doi: 10.1007/s12185-022-03518-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12185-022-03518-2</ArticleId><ArticleId IdType="pmc">PMC9909639</ArticleId><ArticleId IdType="pubmed">36757522</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung S, Yagi Y, Fukushima K, et al. Successful dual antiviral therapy with remdesivir and ensitrelvir in a case of prolonged COVID-19 following B-cell depleting immunotherapy for malignant lymphoma. IDCases. 2023;34:e01890. doi: 10.1016/j.idcr.2023.e01890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idcr.2023.e01890</ArticleId><ArticleId IdType="pmc">PMC10482734</ArticleId><ArticleId IdType="pubmed">37693339</ArticleId></ArticleIdList></Reference><Reference><Citation>Furuya C, Yasuda H, Hiki M, et al. Case report: ensitrelvir for treatment of persistent COVID-19 in lymphoma patients: a report of two cases. Front Immunol. 2024;15:1287300. doi: 10.3389/fimmu.2024.1287300.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2024.1287300</ArticleId><ArticleId IdType="pmc">PMC10850233</ArticleId><ArticleId IdType="pubmed">38333218</ArticleId></ArticleIdList></Reference><Reference><Citation>Marangoni D, Antonello RM, Coppi M, et al. Combination regimen of nirmatrelvir/ritonavir and molnupiravir for the treatment of persistent SARS-CoV-2 infection: a case report and a scoping review of the literature. Int J Infect Dis. 2023;133:53–56. doi: 10.1016/j.ijid.2023.04.412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2023.04.412</ArticleId><ArticleId IdType="pmc">PMC10198768</ArticleId><ArticleId IdType="pubmed">37150351</ArticleId></ArticleIdList></Reference><Reference><Citation>Wee LE, Tan JY, Oon LLE, et al. Relapsing COVID-19 infection as a manifestation of Good syndrome: a case report and literature review. Int J Infect Dis. 2023;129:236–239. doi: 10.1016/j.ijid.2022.12.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2022.12.040</ArticleId><ArticleId IdType="pmc">PMC9809144</ArticleId><ArticleId IdType="pubmed">36608786</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S, Multani A, Garrigues JM, et al. Transient SARS-CoV- 2 RNA-dependent RNA polymerase mutations after remdesivir treatment for chronic COVID-19 in two transplant recipients: case report and intra-host viral genomic investigation. Microorganisms. 2023;11(8):2096. doi: 10.3390/microorganisms11082096.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms11082096</ArticleId><ArticleId IdType="pmc">PMC10460003</ArticleId><ArticleId IdType="pubmed">37630656</ArticleId></ArticleIdList></Reference><Reference><Citation>Carujo A, Ferreira L, Bergantim R, Santos Silva A, Vasconcelos AL. Relapsing COVID-19 in a patient with non-hodgkin lymphoma on chemotherapy. Cureus. 2023 doi: 10.7759/cureus.49974. . Published online December 5.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.49974</ArticleId><ArticleId IdType="pmc">PMC10766046</ArticleId><ArticleId IdType="pubmed">38179390</ArticleId></ArticleIdList></Reference><Reference><Citation>Villaseñor-Echavarri R, Gomez-Romero L, Martin-Onraet A, et al. SARS-CoV-2 genome variations in viral shedding of an immunocompromised patient with non-hodgkin’s lymphoma. Viruses. 2023;15(2):377. doi: 10.3390/v15020377.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15020377</ArticleId><ArticleId IdType="pmc">PMC9962578</ArticleId><ArticleId IdType="pubmed">36851588</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailly B, Péré H, Veyer D, et al. Persistent coronavirus disease 2019 (COVID-19) in an immunocompromised host treated by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-Specific monoclonal antibodies. Clin Infect Dis. 2022;74(9):1706–1707. doi: 10.1093/cid/ciab868.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab868</ArticleId><ArticleId IdType="pmc">PMC8522390</ArticleId><ArticleId IdType="pubmed">34598278</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabañero-Navalon MD, Garcia-Bustos V, Ruiz-Rodriguez P, et al. Persistent SARS-CoV-2 infection with repeated clinical recurrence in a patient with common variable immunodeficiency. Clin Microbiol Infect. 2022;28(2):308–310. doi: 10.1016/j.cmi.2021.10.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.10.021</ArticleId><ArticleId IdType="pmc">PMC8579735</ArticleId><ArticleId IdType="pubmed">34774757</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi S, Klein J, Robertson AJ, et al. De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report. Nat Commun. 2022;13(1):1547. doi: 10.1038/s41467-022-29104-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-29104-y</ArticleId><ArticleId IdType="pmc">PMC8930970</ArticleId><ArticleId IdType="pubmed">35301314</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez MA, Chen TY, Choi H, et al. Extended remdesivir infusion for persistent coronavirus disease 2019 infection. Open Forum Infect Dis. 2022;9(8):ofac382. doi: 10.1093/ofid/ofac382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac382</ArticleId><ArticleId IdType="pmc">PMC9384609</ArticleId><ArticleId IdType="pubmed">36039098</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombo D, Gatti A, Alabardi P, et al. COVID-19-Associated pneumonia in a B-Cell-Depleted patient with non-hodgkin lymphoma: recovery with hyperimmune plasma. J Hematol. 2022;11(2):77–80. doi: 10.14740/jh845.</Citation><ArticleIdList><ArticleId IdType="doi">10.14740/jh845</ArticleId><ArticleId IdType="pmc">PMC9076145</ArticleId><ArticleId IdType="pubmed">35573753</ArticleId></ArticleIdList></Reference><Reference><Citation>Thornton CS, Huntley K, Berenger BM, et al. Prolonged SARS-CoV-2 infection following rituximab treatment: clinical course and response to therapeutic interventions correlated with quantitative viral cultures and cycle threshold values. Antimicrob Resist Infect Control. 2022;11(1):28. doi: 10.1186/s13756-022-01067-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13756-022-01067-1</ArticleId><ArticleId IdType="pmc">PMC8817557</ArticleId><ArticleId IdType="pubmed">35123573</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>